In vitro/in vivo evaluation of the efficiency of teicoplanin-loaded biodegradable microparticles formulated for implantation to infected bone defects.
Chronic osteomyelitis is still the cause of many problems in orthopaedics in terms of therapy and infection persistence. Four-to-six week systemic antibiotic therapy is required along with bone and soft tissue debridement in the therapy of chronic osteomyelitis. Prolonged-release local antibiotic therapy has been taken into consideration due to the side effects encountered in long-term high dose antibiotic use and the duration of hospitalization of the patients. Although local antibiotic therapy has been achieved by bone cement, a second surgical operation is needed for the removal of the system. On the other hand, heat generation during cement curing limits the use of heat-sensitive active ingredients. The most frequent osteomyelitis inducing micro-organism is gram (+) Staphylococcus aureus. In this study, teicoplanin, a glycopeptide antibiotic, active on gram (+) bacteria, was incorporated in a synthetic polymer in order to prepare a microsphere formulation for implantation to bone defects. Particle size, surface characteristics, loading capacity and in vitro release characteristics of the microspheres were determined as well as stability assessment of teicoplanin under accelerated conditions. In vivo studies were performed on rabbits and the microparticles were implanted intra-articularly to the lateral condylus of the femur. Antibiotic presence was detected by a microbiological assay from synovial fluid sample aspirated throughout 5 weeks. In the light of these evaluations, microspheres prepared from PLGA (75:25) (Mw 136,000) polymer were determined to be effective, and promising for obtaining prolonged local antibiotic release.
Haceteppe University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Sihhiye-Ankara, Turkey.
I
I
Yenice
S
S
Caliş
B
B
Atilla
H S
HS
Kaş
M
M
Ozalp
M
M
Ekizoğlu
H
H
Bilgili
A A
AA
Hincal
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000032:analysis; D001672:Biocompatible Materials; D001673:Biodegradation, Environmental; D001850:Bone Diseases, Infectious / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D004339:Drug Compounding / Q000379:methods; D019344:Lactic Acid; D008826:Microbial Sensitivity Tests / Q000379:methods; D008855:Microscopy, Electron, Scanning / Q000379:methods; D008863:Microspheres; D010019:Osteomyelitis / Q000150:complications; D010316:Particle Size; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers; D011817:Rabbits; D013203:Staphylococcal Infections / Q000188:drug therapy; D013582:Synovial Fluid / Q000378:metabolism; D017334:Teicoplanin / Q000008:administration & dosage* / Q000032:analysis; D013997:Time Factors
D000900:Anti-Bacterial Agents; D001672:Biocompatible Materials; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D011108:Polymers; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D017334:Teicoplanin